Team creates Artificial Intelligence platform to tackle rare diseases

"Our technology platform allows us to predict therapies with significantly higher accuracy and safety, much faster than conventional approaches. We are changing the whole model”, Tim observed.

The founders decided to create this tech startup when they heard about Matt Might and his son who was diagnosed with a new rare disease called NGLY1 Disorder.
"The medical profession told him there was no hope and no treatment. After reading his personal story in the New Yorker, we contacted him to help find a treatment for his son. Subsequently, we realised Matt and Bertrand were not alone," the CEO described.

The team developed an AI platform, HealNet, that allows a new model for drug discovery to emerge: a model that operates in a faster and more cost-effective way, which improves the chances of clinical success massively.

With the HealNet AI platform, the team plans to deploy it at scale and find cures for 100 rare diseases by 2025. They’re also working on data layer integrations and precision medicine.

"Once AI will be fully integrated, it will automate the structuring and consolidation of facts within medical data, learn from these facts, and apply the knowledge to discover putative therapeutic interventions even before the disease is affecting the individual. The future of medicine is set to be faster, cheaper and far more efficient," he added.

Adapted from: https://bit.ly/2nLGqxl

More info: https://healx.io/